SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Schachter SC. The new wave of anticonvulsant: focus on levetiracetam oxcarbazepine and zonisamide. CNS Drugs 2000;14:22949.
  • 2
    Van Vleymen B & Van Zandijcke M. Piracetam in the treatment of myoclonus: an overview. Acta Neurol Belg 1996;96:27080.
  • 3
    Haria M & Balfour JA. Levetiracetam. CNS Drugs 1997;7:15964.
  • 4
    Loscher W & Honack D. Profile of ucb LO59, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993;232:14758.
  • 5
    Gower AJ, Noyer M, Verloes R, et al. ucb LO59, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992;222:193203.
  • 6
    Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb LO59) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284:4749.
  • 7
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:7785.DOI: 10.1016/s0163-7258(99)00052-2
  • 8
    Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34:141.DOI: 10.1016/s0920-1211(98)00108-9
  • 9
    Walker MC & Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995;65:35184.
  • 10
    Hutt AJ & Tan SC. Drug chirality and its clinical significance. Drugs 1996;52(suppl 5):112.
  • 11
    Lin JH & Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:40349.
  • 12
    Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1993;24:44152.
  • 13
    Taylor CP, Vartanian MG, Yuen P-W, et al. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res 1993;14:115.
  • 14
    Volosov A, Xiadong S, Perucca E, et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999;66:54753.
  • 15
    Eriksson T, Björkman S, Roth B, et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995;7:4452.
  • 16
    Yang SK & Lu X. Racemization kinetics of enantiomeric oxazepams and stereoselective hydrolysis of enantiomeric oxazepam acetates in rat liver microsomes and brain homogenate. J Pharm Sci 1989;78:78995.
  • 17
    Sanins SM, Adams WJ, Kaiser DG, et al. Mechanistic studies on the metabolic chiral inversion of R-ibuprofen in the rat. Drug Metab Dispos 1991;19:40541.
  • 18
    Isoherranen N, Roeder M, Soback S, et al. Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. J Chromatogr B 2000;745:32532.
  • 19
    Gibaldi M & Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
  • 20
    Lin JH. Species similarities and differences in pharmacokinetics [Review]. Drug Metab Dispos 1995;23:100821.
  • 21
    Davies B & Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:10935.
  • 22
    Levy RH & Boddy AV. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991;8:5516.
  • 23
    Dahl-Puustinen M-L, Perry TL Jr, Dumont E, et al. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. Clin Pharmacol Ther 1989;45:6506.
  • 24
    Okazaki O, Kojima C, Hakusui H, et al. Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother 1991;35:21069.
  • 25
    Boulton DW & Fawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996;41:3540.
  • 26
    Ujhelyi MR, Bottorff MB, Schur M, et al. Aging effects on the organic base transporter and stereoselective renal clearance. Clin Pharmacol Ther 1997;62:11728.
  • 27
    Doheny HC, Ratnaraj N, Whittington MA, et al. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb LO59) in the rat. Epilepsy Res 1999;34:1618.DOI: 10.1016/s0920-1211(98)00104-1
  • 28
    Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991;20:11422.
  • 29
    Haj-Yehia A, Hadad S, Bialer M. Pharmacokinetic evaluation of the structural requirements for a stable valpromide analog. Pharm Res 1992;9:105863.
  • 30
    Bialer M, Haj-Yehia A, Badir K, et al. Can we develop improved derivatives of valproic acid? Pharm World Sci 1994;16:26.